icon-    folder.gif   Conference Reports for NATAP  
  IAS 2017: Conference on HIV Pathogenesis
Treatment and Prevention
Paris, France
July 23-26 2017
Back grey_arrow_rt.gif
Dolutegravir-Lamivudine as initial therapy in HIV-1 infected, ARV-naïve patients: 96 week results of the PADDLE trial
  Download the PDF here
IAC 2016 - Dolutegravir-Lamivudine as initial therapy in HIV-Infected, ARV naïve patients 48 Week Results of the PADDLE trial. - (07/26/16)
Reported by Jules Levin
9th IAS Conference on HIV Science (IAS 2017), July 23-26, 2017, Paris
Authors: M.I. Figueroa1, M.J. Rolón1, P. Patterson1, A. Gun2, P. Cahn1,O. Sued1 Affiliation: 1Fundacion Huésped, Clinical Research, Buenos Aires, Argentina,2Fundacion Huesped, Laboratory research, Buenos Aires, Argentina